A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
- Registration Number
- NCT04023877
- Lead Sponsor
- Eisai Inc.
- Brief Summary
The primary objective of the study is to achieve mass balance recovery of \[14C\]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 8
Inclusion Criteria
Participants must meet all of the following criteria to be included in this study:
- Body Mass Index (BMI) of 18 to 30 kilogram per square meter (kg/m^2) at Screening
Exclusion Criteria
Participants who meet any of the following criteria will be excluded from this study:
- Have participated in a [14C]-research study within the 6 months prior to Day -1
- Exposure to clinically significant radiation (greater than [>] 100 millisieverts) within 12 months prior to Day -1
- Clinically significant illness that required medical treatment within 8 weeks or a clinically significant infection that required medical treatment within 4 weeks before dosing
- Any history of abdominal surgery that may affect pharmacokinetic profiles of study drug (example, hepatectomy, nephrectomy, digestive organ resection but not cholecystectomy nor appendectomy) at Screening or Baseline
- Any other clinically abnormal symptom or organ impairment found by medical history, physical examinations, vital signs, ECG finding (including PR > 210 millisecond [msec], QRS > 110 msec), or laboratory test results that required medical treatment at Screening or Baseline
- A prolonged QT/QTc interval (QTcF > 450 msec) as demonstrated by ECGs at Screening or Baseline
- Systolic blood pressure > 130 millimetres of mercury (mmHg) or diastolic blood pressure > 85 mmHg at Screening or Baseline
- Heart rate less than (<) 45 beats per minute (beats/min) or >100 beats/min at Screening or Baseline
- Known history of clinically significant drug allergy at Screening or Baseline
- Known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening or Baseline
- Known to be human immunodeficiency virus (HIV) positive at Screening
- Active viral hepatitis (A, B, or C) as demonstrated by positive serology at Screening
- History of drug or alcohol dependency or abuse within the 2 years before Screening, or those who have a positive urine drug or alcohol test at Screening or Baseline
- Use of tobacco or nicotine-containing products within 4 weeks before dosing
- Currently enrolled in another clinical trial or used any investigational drug or device within 30 days (or 5 half-lives, whichever is longer) preceding informed consent
- Engagement in strenuous exercise within 2 weeks before dosing (example, marathon runners, weight lifters)
- Intake of caffeinated beverages or caffeinated food within 72 hours before dosing
- Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect the various drug metabolizing enzymes and transporters (example, alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or orange juice, vegetables from the mustard green family [example, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard], and charbroiled meats) within 1 week before dosing
- Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing Intake of over-the-counter (OTC) medications within 14 days (or 5 half-lives, whichever is longer) before dosing unless the investigator and sponsor medical monitor consider that they do not compromise participant safety or study assessments
- Use of any prescription drugs within 4 weeks before dosing
- Use of illegal recreational drugs
- Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week of dosing
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description E2027 E2027 Participants will receive approximately 130 microcurie (μCi) of \[14C\]E2027 as a single 50 milligram (mg) (free base), capsule, orally on Day 1.
- Primary Outcome Measures
Name Time Method Time to Reach Maximum (Peak) Concentration (Tmax) of Radiolabeled [14C]E2027, Non-Radiolabeled E2027 and Metabolites in Biological Matrices Pre-dose up to Day 56 post-dose Cumulative Percent of the Radiolabeled Dose of [14C]E2027 in Biological Matrices (Blood, Urine, Feces and Toilet Tissue) Up to 56 days Blood, urine, feces and toilet tissue samples will be collected at specific time points and will be analyzed for the amount of radiolabeled \[14C\]E2027.
Maximum Concentration (Cmax) of Radiolabeled [14C]E2027, Non-Radiolabeled E2027 and Metabolites in Biological Matrices Pre-dose up to Day 56 post-dose Area Under the Concentration-Time Curve From Time Zero to 24 hours (AUC(0-24h)) of Radiolabeled [14C]E2027, Non-Radiolabeled E2027 and Metabolites in Biological Matrices Pre-dose up to Day 56 post-dose Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUC(0-t)) of Radiolabeled [14C]E2027, Non-Radiolabeled E2027 and Metabolites in Biological Matrices Pre-dose up to Day 56 post-dose Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC(0-inf)) of Radiolabeled [14C]E2027, Non-Radiolabeled E2027 and Metabolites in Biological Matrices Pre-dose up to Day 56 post-dose Terminal Elimination Half-life (t1/2) of Radiolabeled [14C]E2027, Non-Radiolabeled E2027 and Metabolites in Biological Matrices Pre-dose up to Day 56 post-dose Apparent Total Body Clearance (CL/F) of E2027 in Biological Matrices Pre-dose up to Day 56 post-dose Apparent Volume of Distribution (Vd/F) of E2027 in Biological Matrices Pre-dose up to Day 28 post-dose Percent of AUC(0-inf) of Metabolite to E2027 in Biological Matrices Pre-dose up to Day 28 post-dose
- Secondary Outcome Measures
Name Time Method Number of Participants With Clinically Significant Abnormal Vital Sign Values Up to 56 days post-dose Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Up to 56 days post-dose Number of Participants With Clinically Significant Abnormal Laboratory Values Up to 56 days post-dose Number of Participants With Clinically Significant Abnormal Physical Examination Findings Baseline, Up to 56 days post-dose Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings Up to 56 days post-dose
Trial Locations
- Locations (1)
Covance Clinical Research Unit Inc.
🇺🇸Madison, Wisconsin, United States
Covance Clinical Research Unit Inc.🇺🇸Madison, Wisconsin, United States